

VITROLIFE GROUP™

Group call with analysts
2025-12-16

Bronwyn Brophy O'Connor, CEO
Pär Ihrskog, CFO

Vitrolife announces genetic services restructuring program targeting annualised savings of 65 MSEK and recognises a 5.4 BSEK goodwill impairment

- Vitrolife conducts a strategic review of its genetic services portfolio and markets.
- Decided to:
 - discontinue two genetic test lines (GPDx and NACE)
 - exit low profit markets within the genetic services business.Together, this accounts for 2-3% of the Group's revenue.
- Restructuring costs of 55 MSEK will be recorded in Q4 2025.
- Expected to impact approximately 6% of Vitrolife's workforce.
- Targeting annualised savings of 65 MSEK, expected to have a positive impact in the first half of 2026, and to reach full effect at the end of the third quarter of 2026.
- As a result of the strategic review, Vitrolife will, in accordance with IFRS accounting standards, record a SEK 5.4 billion impairment in Q4 2025 relating to goodwill associated with the Igenomix acquisition.
- The impairment is a consequence of the outcome of the strategic review showing lower than expected market growth for parts of the genetic services product portfolio and an increased discount factor (WACC).